ACOR
(NASDAQ)
1.06
-0.0050  (-0.47%)
Volume (24h): 777.82K Day Range: 1.04 - 1.17
Market Cap: 50.88M 52W Range: 0.7001 - 13.53
Mar-17-20 04:00PM What Makes Acorda (ACOR) a New Buy StockZacks
Mar-14-20 03:30PM Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report?Zacks
Feb-24-20 12:00PM Acorda Therapeutics to Present at Cowen Annual Health Care ConferenceBusiness Wire
Feb-18-20 06:44AM Edited Transcript of ACOR earnings conference call or presentation 13-Feb-20 1:30pm GMTThomson Reuters StreetEvents
Feb-17-20 04:11PM Edited Transcript of ACOR earnings conference call or presentation 13-Feb-20 1:30pm GMTThomson Reuters StreetEvents
Feb-14-20 04:57PM Acorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/YZacks
Feb-13-20 03:25PM Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue EstimatesZacks
02:15PM Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4Zacks
Feb-13-20 12:00PM Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial ResultsBusiness Wire
Feb-10-20 03:20PM What's in Store for Acorda (ACOR) This Earnings Season?Zacks
Feb-06-20 05:31PM Earnings Preview: Acorda Therapeutics (ACOR) Q4 Earnings Expected to DeclineZacks
10:51AM Acorda Therapeutics, Inc. (NASDAQ:ACOR): What Does Its Beta Value Mean For Your Portfolio?Simply Wall St.
Jan-30-20 12:00PM Acorda Fourth Quarter/Year End 2019 Update: Webcast/Conference Call Scheduled for February 13, 2020Business Wire
Jan-24-20 01:54PM Implied Volatility Surging for Acorda (ACOR) Stock OptionsZacks
Jan-15-20 12:00PM Acorda Provides 2019 Highlights and 2020 Guidance at J.P. Morgan Healthcare ConferenceBusiness Wire
Jan-08-20 12:00PM Acorda to Present at the 38th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
Jan-07-20 03:55PM Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% HigherZacks
Jan-03-20 12:55PM The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate MergerBenzinga
Dec-26-19 12:00PM Acorda Therapeutics Completes Exchange of $276 Million of its 1.75% Convertible Senior Notes due June 2021; New Convertible Secured Notes Mature December 2024Business Wire
Dec-23-19 10:30AM Acorda Therapeutics Announces Private Exchange of $276 Million of Its 1.75% Convertible Senior Notes Due 2021Business Wire
Dec-12-19 03:31PM Hedge Funds Are Getting Burned By Acorda Therapeutics Inc (ACOR)Insider Monkey
Dec-04-19 04:30PM Acorda (ACOR) Down 13.5% Since Last Earnings Report: Can It Rebound?Zacks
Dec-02-19 03:22PM Acorda (ACOR) Down More Than 80% Year to Date: Here's WhyZacks
Nov-27-19 12:00PM Acorda Therapeutics Elects John Kelley Chair, Board of DirectorsBusiness Wire
Nov-12-19 12:00PM Acorda Therapeutics Announces Departure of President, International & General CounselBusiness Wire
Nov-08-19 03:21PM Is Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Paid Enough Relative To Peers?Simply Wall St.
Nov-07-19 04:08PM Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line SalesZacks
04:05PM Horizon Therapeutics' (HZNP) Q3 Earnings Beat EstimatesZacks
Nov-07-19 04:04PM Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3Zacks
01:50PM Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%Zacks
Nov-06-19 09:40PM Were Hedge Funds Right About Dumping Acorda Therapeutics Inc (ACOR)?Insider Monkey
09:28PM Edited Transcript of ACOR earnings conference call or presentation 4-Nov-19 9:30pm GMTThomson Reuters StreetEvents
Nov-06-19 04:33PM Edited Transcript of ACOR earnings conference call or presentation 4-Nov-19 9:30pm GMTThomson Reuters StreetEvents
03:56PM Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS ViewZacks
Nov-06-19 03:34PM Intercept (ICPT) Earnings and Sales Miss Estimates in Q3Zacks
Nov-05-19 04:45PM Acorda (ACOR) Q3 Earnings and Revenues Surpass EstimatesZacks
04:09PM Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/YZacks
Nov-04-19 10:25PM Acorda Therapeutics (ACOR) Reports Q3 Loss, Tops Revenue EstimatesZacks
09:00PM Acorda Provides Update for Third Quarter Ended September 30, 2019Business Wire
Nov-04-19 04:18PM AMAG Q3 Loss Wider Than Expected, Revenues Lag EstimatesZacks
Nov-01-19 06:49PM Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 GuidanceZacks
04:07PM Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues MissZacks
Oct-31-19 04:40PM Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3Zacks
04:33PM Vertex (VRTX) Q3 Earnings Beat, Revenues Lag EstimatesZacks
Oct-31-19 03:54PM Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 LossZacks
01:26PM Insmed (INSM) in Focus: Stock Moves 7.1% HigherZacks
Oct-28-19 02:32PM Acorda Therapeutics (ACOR) Expected to Beat Earnings Estimates: Should You Buy?Zacks
Oct-25-19 11:12AM The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart DrugBenzinga
Oct-24-19 03:24PM Acorda (ACOR) to Post Q3 Earnings: What's in the Cards?Zacks
11:36AM The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-RaiseBenzinga
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)